Stelara: Better Persistency, Lower Discontinuation Rates in Psoriasis Study
New findings from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) indicate significantly better persistency and lower rates of discontinuation therapy with Stelara (ustekinumab; Jannsen Biotech) compared with anti-tumor necrosis factor (TNF)-alpha treatments. The results from the study have been reported at the annual meeting of the European Academy of Dermatology and Venereology (EADV).
PSOLAR is a longitudinal observation study evaluating safety and clinical outcomes for patients with psoriasis, comparing Stelara, infliximab, adalimumab, etanercept, and other conventional systemic agents. In this analysis regarding duration of treatment (length in days between first dose of treatment and discontinuation of treatment, switch to a different treatment, registry withdrawal, or the most recent data collection, depending on which occurred first) and persistence (time to therapy stop/switch), significantly better persistence was observed with Stelara vs. other biologics among first-line use (adalimumab vs. Stelara: HR 4.99; confidence interval (CI): 3.39–7.35; P<0.0001; etanercept vs. Stelara: HR 5.59; CI: 3.77–8.29; P<0.0001; infliximab vs. Stelara: HR 3.04; CI: 1.66–5.57; P=0.0003). Similar results were observed among the second- and third-line patient groups, in which Stelara showed better treatment longevity and fewer discontinuations vs. other biologics. No significant differences were observed among reasons for stop/switch across all four biologics.
Stelara is a human interleukin (IL)-12 and IL-23 antagonist approved for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen plus UVA), as well as for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate, alone or in combination with MTX.
For more information visit Janssen.com.